37.6k views
2 votes
Staging CLL:
If LAD?
If splenomegaly>
If anemia?
If thrombocytopenia?

User Katmoon
by
8.4k points

1 Answer

2 votes

Final answer:

Chronic Lymphocytic Leukemia (CLL) staging involves assessing the presence of lymphadenopathy, splenomegaly, anemia, and thrombocytopenia. An enlarged spleen in CLL is due to extramedullary hemopoiesis, while anemia and thrombocytopenia are often due to the displacement of normal bone marrow cells. Patients with acute myelogenous leukemia typically experience an impaired production of erythrocytes due to the proliferation of abnormal myeloid cells.

Step-by-step explanation:

The question pertains to the staging of Chronic Lymphocytic Leukemia (CLL), which involves various factors including lymphadenopathy (LAD), splenomegaly, anemia, and thrombocytopenia. The staging of CLL takes into account the presence of these conditions, each of which can indicate the progression of the disease.

CLL is a type of cancer that originates in the bone marrow and leads to excessive production of abnormal lymphocytes. These lymphocytes accumulate in the blood and certain organs, causing various symptoms and complications. Staging helps determine the extent of the disease and guides treatment.

LAD refers to the enlargement of lymph nodes and is a common sign in CLL due to the accumulation of malignant lymphocytes. It often requires more detailed examination to assess extent and potential impact on prognosis.

Splenomegaly is characterized by an enlarged spleen and can occur in CLL as a result of extramedullary hemopoiesis. The spleen becomes overactive in removing and destroying blood cells, leading to various symptoms and an increased risks, such as rupturing.

Anemia in CLL occurs when red blood cells (erythrocytes) are reduced, leading to fatigue and weakness. Thrombocytopenia refers to a low platelet count and increases the risk of bleeding and bruising. Both conditions can be a result of bone marrow displacement by cancerous cells or treatment effects.

In response to question 31, a patient with acute myelogenous leukemia (AML) would likely experience an impaired production of erythrocytes. AML predominantly affects the myeloid line of cells, which includes erythrocytes, myeloblasts, and megakaryocytes (precursors to platelets). The rapid proliferation of abnormal myeloblasts in the bone marrow impairs the production of normal blood cells.

User Tobias Domhan
by
7.3k points